This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by PARK, S.
Right arrow Articles by SOUMERAI, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PARK, S.
Right arrow Articles by SOUMERAI, S. B.
The British Journal of Psychiatry (2005) 187: 137-142
© 2005 The Royal College of Psychiatrists

Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia

Population-based study

SYLVIA PARK, PhD

Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, USA, and Korea Health Industry Development Institute, Seoul, Korea

DENNIS ROSS-DEGNAN, ScD, ALYCE S. ADAMS, PhD and JAMES SABIN, MD

Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, USA

PANOS KANAVOS, PhD

London School of Economics and Political Science, London, UK

STEPHEN B. SOUMERAI, ScD

Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, USA

Correspondence: Dr Sylvia Park, Korea Health Industry Development Institute, 57-1Noryangjin-Dong, Dongjak-GU, Seoul 156-800, Republic of Korea. E-mail: sylviap{at}khidi.or.kr

Declaration of interest None. Funding detailed in Acknowledgements.

Background The extent to which atypical antipsychotics have a lower incidence of extrapyramidal symptoms than typical antipsychotics has not been well-evaluated in community practice.

Aims To examine the effects of switching antipsychotics on antiparkinsonian medication use among individuals with schizophrenia in UK general practices.

Method We included those switched from typical to atypical antipsychotics (n=209) or from one typical antipsychotic to another (n=261) from 1994 to 1998.

Results Antiparkinsonian drug prescribing dropped by 9.2% after switching to atypical antipsychotics (P<0.0001). Switching to olanzapine decreased the rate by 19.2% (P<0.0001), but switching to risperidone had no impact. After switching from one typical antipsychotic to another, antiparkinsonian drug prescribing increased by 12.9% (P<0.0001).

Conclusions Reduction in antiparkinsonian medication use after switching to atypical antipsychotics was substantial in community practice but not as large as in randomised controlled trials. The rate of reduction varied according to the type of medication.


Related articles in BJP:

Highlights of this issue
KIMBERLIE DEAN
BJP 2005 187: 101-a5. [Full Text]  

PETER TYRER
BJP 2005 187: 202. [Full Text]  



This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
S. Grover and P. Kulhara
Antiparkinsonian prescription and extrapyramidal symptoms
The British Journal of Psychiatry, May 1, 2006; 188(5): 492 - 492.
[Full Text] [PDF]

Home page
 J PsychopharmacolHome page
P. J. Weiden
Switching antipsychotics: an updated review with a focus on quetiapine
J Psychopharmacol, January 1, 2006; 20(1): 104 - 118.
[Abstract] [PDF]